Download PDF
Thromb Haemost 2018; 118(03): 601-612
DOI: 10.1055/s-0038-1629896
Atherosclerosis and Ischaemic Disease
Schattauer GmbH Stuttgart

Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size

Mohamed Farag
,
Nikolaos Spinthakis
,
Manivannan Srinivasan
,
Keith Sullivan
,
David Wellsted
,
Diana A. Gorog
 Funding This work was supported by the Research & Development Department, East and North Hertfordshire NHS Trust.
Further Information

Publication History

28 September 2017

21 December 2017

Publication Date:
14 February 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which may delay gastric transit and reduce DAPT absorption. We sought to assess the effect of morphine on reperfusion, infarct size and thrombotic status in 300 patients presenting for PPCI. Morphine was given in a non-randomized fashion as required by emergency teams en route to the heart attack centre. All patients received DAPT and PPCI according to standard care, with optional glycoprotein IIb/IIIa inhibitor (GPI) use. Patients were assessed for ST-segment resolution, coronary flow, thrombotic status and peak troponin. Patients receiving morphine (n = 218; 72.7%) experienced less spontaneous ST-segment resolution pre-PPCI, lower rate of TIMI 2/3 flow in the infarct-related artery pre-PPCI and higher peak troponin level post-PPCI (median [interquartile range]; 1,906 [1,002–4,398] vs. 1,268 [249–2,920] ng/L; p = 0.016) than those who did not. Patients receiving morphine exhibited significantly enhanced platelet reactivity and impaired endogenous fibrinolysis on arrival, compared with no-morphine patients. Morphine administration was an independent predictor of failure of spontaneous ST-segment resolution after adjustment for other variables (odds ratio: 0.26; confidence interval: 0.08–0.84; p = 0.025). Among patients receiving GPI, there was no difference in pre-PPCI flow or peak troponin according to morphine use, suggesting that the adverse effects of morphine relate to delayed DAPT absorption, which may be overcome by GPI. Our hypothesis-generating data suggest that morphine use in STEMI is associated with enhanced platelet reactivity, reduced spontaneous myocardial reperfusion (pre-PPCI) and larger infarct size, and these adverse effects may be influenced by GPI use.

Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02562690.

Keywords

opiates - morphine - percutaneous coronary intervention - thrombosis - endogenous fibrinolysis
 

  • References

  • 1 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2017; 39 (02) 119-177
    PubMedGoogle Scholar
  • 2 Hobl EL, Stimpfl T, Ebner J. , et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63 (07) 630-635
    CrossrefPubMedGoogle Scholar
  • 3 Bellandi B, Zocchi C, Xanthopoulou I. , et al. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol 2016; 221: 567-571
    CrossrefPubMedGoogle Scholar
  • 4 Kubica J, Adamski P, Ostrowska M. , et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37 (03) 245-252
    CrossrefPubMedGoogle Scholar
  • 5 Parodi G, Valenti R, Bellandi B. , et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61 (15) 1601-1606
    CrossrefPubMedGoogle Scholar
  • 6 Thomas MR, Morton AC, Hossain R. , et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost 2016; 116 (01) 96-102
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Silvain J, Storey RF, Cayla G. , et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116 (02) 369-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Parodi G, Bellandi B, Xanthopoulou I. , et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014; 8 (01) e001593
    CrossrefPubMedGoogle Scholar
  • 9 Parodi G, Xanthopoulou I, Bellandi B. , et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 2015; 65 (05) 511-512
    CrossrefPubMedGoogle Scholar
  • 10 Steg PG, James SK, Atar D. , et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
    CrossrefPubMedGoogle Scholar
  • 11 Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 2010; 55 (19) 2107-2115
    CrossrefPubMedGoogle Scholar
  • 12 de Lemos JA, Antman EM, Giugliano RP. , et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol 2000; 85 (03) 299-304
    CrossrefPubMedGoogle Scholar
  • 13 Thygesen K, Alpert JS, Jaffe AS. , et al; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J 2012; 33 (20) 2551-2567
    CrossrefPubMedGoogle Scholar
  • 14 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 15 Bainey KR, Fu Y, Wagner GS. , et al; ASSENT 4 PCI Investigators. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J 2008; 156 (02) 248-255
    CrossrefPubMedGoogle Scholar
  • 16 Fefer P, Hod H, Hammerman H, Boyko V, Behar S, Matetzky S. ; Acute Coronary Syndrome Israeli Survey (ACSIS) 2006 Study Group. Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Am J Cardiol 2009; 103 (02) 149-153
    CrossrefPubMedGoogle Scholar
  • 17 Giannitsis E, Steen H, Kurz K. , et al. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. J Am Coll Cardiol 2008; 51 (03) 307-314
    CrossrefPubMedGoogle Scholar
  • 18 Arruda-Olson AM, Roger VL, Jaffe AS, Hodge DO, Gibbons RJ, Miller TD. Troponin T levels and infarct size by SPECT myocardial perfusion imaging. JACC Cardiovasc Imaging 2011; 4 (05) 523-533
    CrossrefPubMedGoogle Scholar
  • 19 de Waha S, Eitel I, Desch S. , et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol 2015; 104 (09) 727-734
    CrossrefPubMedGoogle Scholar
  • 20 Gurbel PA, Jeong YH, Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside. Circ Res 2016; 118 (09) 1380-1391
    CrossrefPubMedGoogle Scholar
  • 21 Goto S, Tamura N, Ishida H, Ruggeri ZM. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5′-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006; 47 (01) 155-162
    CrossrefPubMedGoogle Scholar
  • 22 Cosemans JM, Munnix IC, Wetzker R, Heller R, Jackson SP, Heemskerk JW. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006; 108 (09) 3045-3052
    CrossrefPubMedGoogle Scholar
  • 23 Hosokawa K, Ohnishi T, Fukasawa M. , et al. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 2012; 83 (02) 154-161
    CrossrefPubMedGoogle Scholar
  • 24 Okafor ON, Gorog DA. Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk. J Am Coll Cardiol 2015; 65 (16) 1683-1699
    CrossrefPubMedGoogle Scholar
  • 25 Christopoulos C, Farag M, Sullivan K, Wellsted D, Gorog DA. Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention. Thromb Haemost 2017; 117 (03) 457-470
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Giannopoulos G, Deftereos S, Kolokathis F, Xanthopoulou I, Lekakis J, Alexopoulos D. P2Y12 Receptor Antagonists and Morphine: A Dangerous Liaison?. Circ Cardiovasc Interv 2016; 9 (09) e004229
    CrossrefPubMedGoogle Scholar
  • 27 Hobl EL, Reiter B, Schoergenhofer C. , et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol 2016; 105 (04) 349-355
    CrossrefPubMedGoogle Scholar
  • 28 Hobl EL, Reiter B, Schoergenhofer C. , et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest 2016; 46 (01) 7-14
    CrossrefPubMedGoogle Scholar
  • 29 Kubica J, Kubica A, Jilma B. , et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016; 215: 201-208
    CrossrefPubMedGoogle Scholar
  • 30 McEvoy JW, Ibrahim K, Kickler TS. , et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation with Ticagrelor Inhibition and Fentanyl). Circulation 2018; 137 (03) 307-309
    CrossrefPubMedGoogle Scholar
  • 31 Niezgoda P, Sikora J, Barańska M. , et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost 2017; 117 (04) 718-726
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Siller-Matula JM, Specht S, Kubica J. , et al. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol 2016; 82 (05) 1343-1350
    CrossrefPubMedGoogle Scholar
  • 33 Cuisset T, Frere C, Quilici J. , et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008; 1 (06) 649-653
    CrossrefPubMedGoogle Scholar
  • 34 De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009; 53 (18) 1668-1673
    CrossrefPubMedGoogle Scholar
  • 35 Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003; 42 (11) 1886-1889
    CrossrefPubMedGoogle Scholar
  • 36 Topol EJ, Moliterno DJ, Herrmann HC. , et al; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344 (25) 1888-1894
    CrossrefPubMedGoogle Scholar
  • 37 Lee DP, Herity NA, Hiatt BL. , et al; TIrofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107 (11) 1497-1501
    CrossrefPubMedGoogle Scholar
  • 38 Windecker S, Kolh P, Alfonso F. , et al; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35 (37) 2541-2619
    CrossrefPubMedGoogle Scholar
  • 39 Marciani L, Wright J, Foley S. , et al. Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2010; 32 (05) 655-663
    PubMedGoogle Scholar
  • 40 Montalescot G, van 't Hof AW, Lapostolle F. , et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedGoogle Scholar